Saturday, 7 May 2016

Depression - Pipeline Review, H1 2016

Depression - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Depression - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Depression
- The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
- The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Depression
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AB Science SA Acetylon Pharmaceuticals, Inc. Ache Laboratorios Farmaceuticos S/A Adamed Sp. z o.o. Addex Therapeutics Ltd Aequus Pharmaceuticals Inc. Alkermes Plc Allergan Plc Alvogen Korea Co., Ltd. Amorsa Therapeutics Inc. Anavex Life Sciences Corp. Angelini Group Angita B.V. AstraZeneca Plc Axsome Therapeutics, Inc. Azevan Pharmaceuticals, Inc. BioCrea GmbH Biogen, Inc. Bionomics Limited Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Calico LLC Cerecor Inc. Clera Inc. D-Pharm Ltd. Delpor, Inc. e-Therapeutics Plc Eisai Co., Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc GliaCure Inc. H. Lundbeck A/S Heptares Therapeutics Limited HolsboerMaschmeyer NeuroChemie GmbH Hua Medicine Ltd. Hyundai Pharmaceutical Co., Ltd. Impel NeuroPharma, Inc. INSYS Therapeutics, Inc. Intas Pharmaceuticals Ltd. Intra-Cellular Therapies, Inc. INVENT Pharmaceuticals, Inc. Johnson & Johnson KemPharm, Inc. Lead Discovery Center GmbH Les Laboratoires Servier SAS Lixte Biotechnology Holdings, Inc. Luye Pharma Group Ltd. M et P Pharma AG Mapi Pharma Ltd. Mapreg S.A.S. Meta-IQ ApS Methylation Sciences Inc. MI.TO. Technology S.r.L. miCure Therapeutics Ltd. Mitsubishi Tanabe Pharma Corporation Neuralstem, Inc. Neurocrine Biosciences, Inc. NeuroNascent, Inc. NeurOp, Inc Newron Pharmaceuticals S.p.A. Nippon Chemiphar Co., Ltd. nLife Therapeutics, S.L. Novartis AG Omeros Corporation Otsuka Holdings Co., Ltd. Pfizer Inc. Pherin Pharmaceuticals, Inc. Polleo Pharma Limited Protagenic Therapeutics Inc. Reviva Pharmaceuticals Inc. Richter Gedeon Nyrt. RTI International Saniona AB SK Biopharmaceuticals Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Supernus Pharmaceuticals, Inc. Suven Life Sciences Ltd. Taisho Pharmaceutical Holdings Co., Ltd. Takeda Pharmaceutical Company Limited Tetra Discovery Partners LLC Trevena, Inc. TRImaran Pharma, Inc. Turing Pharmaceuticals AG VistaGen Therapeutics , Inc. Zhejiang Huahai Pharmaceutical Co., Ltd. Zogenix, Inc. Zysis Limited


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Metastatic Pancreatic Cancer - Pipeline Review, H1 2016

Metastatic Pancreatic Cancer - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Metastatic Pancreatic Cancer - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AbbVie Inc. Aduro BioTech, Inc. ArQule, Inc. Array BioPharma Inc. AstraZeneca Plc Axcentua Pharmaceuticals AB Berg LLC Bionomics Limited Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Celgene Corporation Clovis Oncology, Inc. Cornerstone Pharmaceuticals, Inc. CTI BioPharma Corp. CytRx Corporation Eleison Pharmaceuticals LLC Eli Lilly and Company Ensol Biosciences Inc. Erytech Pharma SA F. Hoffmann-La Roche Ltd. Fountain Biopharma Inc. Gilead Sciences, Inc. GlaxoSmithKline Plc HanAll Biopharma Co., Ltd. Immodulon Therapeutics Ltd. Incyte Corporation MabVax Therapeutics Holdings, Inc. Merck & Co., Inc. Merrimack Pharmaceuticals, Inc. Momenta Pharmaceuticals, Inc. NanoCarrier Co., Ltd. NantKwest, Inc. Natco Pharma Limited NewLink Genetics Corporation Novartis AG Oncolytics Biotech Inc. Oncovir, Inc. Oryx GmbH & Co. KG Pfizer Inc. Pharma Mar, S.A. Pharmacyclics, Inc. Phoenix Biotechnology, Inc. Plexxikon Inc. Precision Biologics, Inc. Redx Pharma Plc Rexahn Pharmaceuticals, Inc. Sanofi Silence Therapeutics Plc Targovax AS Zeria Pharmaceutical Co., Ltd.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Cognitive Impairment - Pipeline Review, H1 2016

Cognitive Impairment - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Cognitive Impairment - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
- The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects
- The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cognitive Impairment

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AbbVie Inc. Addex Therapeutics Ltd AgeneBio Inc. Amarantus Bioscience Holdings, Inc. Astellas Pharma Inc. AstraZeneca Plc Avineuro Pharmaceuticals, Inc. Avraham Pharmaceuticals Ltd. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Cardax Pharmaceuticals, Inc. Cerecor Inc. CereSpir Incorporated Cognition Therapeutics, Inc. Confluence Pharmaceuticals LLC Coronis Partners Ltd. Cortice Biosciences, Inc. D-Pharm Ltd. Eisai Co., Ltd. Eli Lilly and Company Ensol Biosciences Inc. F. Hoffmann-La Roche Ltd. FORUM Pharmaceuticals Inc. Genzyme Corporation H. Lundbeck A/S Heptares Therapeutics Limited Intra-Cellular Therapies, Inc. Iproteos S.L. Luc Therapeutics, Inc. Merck & Co., Inc. Nanotherapeutics, Inc. Neuralstem, Inc. Neuron Biopharma SA Octapharma AG Omeros Corporation Pacific Northwest Biotechnology, LLC Panacea Pharmaceuticals, Inc. Pfizer Inc. Pherin Pharmaceuticals, Inc. Sage Therapeutics, Inc. Saniona AB SeneXta Therapeutics SA Shire Plc SK Biopharmaceuticals Co., Ltd. Spherium Biomed S.L. Sunovion Pharmaceuticals Inc. Suven Life Sciences Ltd. Takeda Pharmaceutical Company Limited Tetra Discovery Partners LLC Therapix Biosciences Ltd Vanda Pharmaceuticals Inc. Vicore Pharma AB Virogenomics BioDevelopment, Inc.




 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Peritoneal Cancer - Pipeline Review, H1 2016

Peritoneal Cancer - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report  provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Mantle Cell Lymphoma - Pipeline Review, H1 2016


Scope

- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AbbVie Inc. Acetylon Pharmaceuticals, Inc. Adaptimmune Therapeutics Plc Aduro BioTech, Inc. Advanced Accelerator Applications SA Advenchen Laboratories, LLC Amgen Inc. Array BioPharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Atara Biotherapeutics, Inc. AVEO Pharmaceuticals, Inc. Bayer AG Boehringer Ingelheim GmbH Boston Biomedical, Inc. Caladrius Biosciences, Inc. Celldex Therapeutics, Inc. Celsion Corporation CerRx, Inc. Cerulean Pharma, Inc. Clovis Oncology, Inc. Corcept Therapeutics Incorporated Critical Outcome Technologies Inc. CritiTech, Inc. CTI BioPharma Corp. Dr. Reddy's Laboratories Limited EirGenix Inc. Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Exelixis, Inc. F. Hoffmann-La Roche Ltd. Galena Biopharma, Inc. Ganymed Pharmaceuticals AG Genelux Corporation Genentech, Inc. Genor BioPharma Co., Ltd. Glycotope GmbH Gradalis Inc. Hemispherx Biopharma, Inc. ImmunoGen, Inc. Immunovaccine, Inc. Incyte Corporation Innate Pharma S.A. Johnson & Johnson Juno Therapeutics Inc. Kyowa Hakko Kirin Co., Ltd. Lee's Pharmaceutical Holdings Limited Mabion SA MabVax Therapeutics Holdings, Inc. MedImmune, LLC Medivation, Inc. Merck & Co., Inc. Millennium Pharmaceuticals, Inc. MolMed S.p.A. Mycenax Biotech Inc. Novartis AG Oasmia Pharmaceutical AB OBI Pharma, Inc. Oncobiologics, Inc. Oncolix, Inc. Oncolytics Biotech Inc. OncoMed Pharmaceuticals, Inc. Ono Pharmaceutical Co., Ltd. Oxford BioMedica Plc OXiGENE, Inc. Pharma Mar, S.A. Pharmacyclics, Inc. PsiOxus Therapeutics Limited Quest PharmaTech Inc. Sanofi Pasteur SA Shenzen SiBiono GeneTech Co., Ltd. Sotio a.s. Synta Pharmaceuticals Corp. TapImmune Inc. Tesaro, Inc. TetraLogic Pharmaceuticals Tyrogenex, Inc. Vascular Biogenics Ltd. VentiRx Pharmaceuticals, Inc.


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Friday, 6 May 2016

Esophageal Cancer - Pipeline Review, H1 2016

Esophageal Cancer - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Esophageal Cancer - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Adaptimmune Therapeutics Plc Advantagene, Inc. Advaxis, Inc. Advenchen Laboratories, LLC Almac Discovery Limited Amgen Inc. ArQule, Inc. Array BioPharma Inc. Aslan Pharmaceuticals Pte. Ltd. ATLAB Pharma SAS Bayer AG Betta Pharmaceuticals Co. Ltd. Boehringer Ingelheim GmbH Celgene Corporation Celldex Therapeutics, Inc. Cellectar Biosciences, Inc. Cerulean Pharma, Inc. Cyclacel Pharmaceuticals, Inc. Genmab A/S Glycotope GmbH Hutchison MediPharma Limited Ignyta, Inc. ImmunoFrontier, Inc. ImmunoGen, Inc. Immunomedics, Inc. Johnson & Johnson Karyopharm Therapeutics, Inc. Komipharm International Co., Ltd. MacroGenics, Inc. Mebiopharm Co., Ltd. MedImmune, LLC Merck & Co., Inc. Novartis AG Omeros Corporation Omnitura Therapeutics Inc. Oncolys BioPharma Inc. Ono Pharmaceutical Co., Ltd. Pfizer Inc. Proteo, Inc. Puma Biotechnology, Inc. Shenzen SiBiono GeneTech Co., Ltd. Shionogi & Co., Ltd. Sihuan Pharmaceutical Holdings Group Ltd. Spectrum Pharmaceuticals, Inc. Symphogen A/S Synta Pharmaceuticals Corp. Taiho Pharmaceutical Co., Ltd. Taiwan Liposome Company, Ltd. Takara Bio Inc. tella Inc TG Therapeutics, Inc. Transgene Biotek Limited VioQuest Pharmaceuticals, Inc. Virocan Therapeutics Private Limited



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Retinopathy Of Prematurity - Pipeline Review, H1 2016

Retinopathy Of Prematurity - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Retinopathy Of Prematurity - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
- The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects
- The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Acucela Inc. Biomar Microbial Technologies F. Hoffmann-La Roche Ltd. Gene Signal International SA Insmed Incorporated


 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Thursday, 5 May 2016

Alcoholic Hepatitis - Pipeline Review, H1 2016

Alcoholic Hepatitis - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack.This report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete report available @ Alcoholic Hepatitis - Pipeline Review, H1 2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects
- The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Alfact Innovation Conatus Pharmaceuticals Inc. Generon (Shanghai) Corporation Ltd. Immuron Limited Intercept Pharmaceuticals, Inc. Promethera Biosciences S.A. Verlyx Pharma Inc.



 Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###